Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, signed a Sponsored Research Agreement with Old Dominion University and the Frank Reidy Research Center for Bioelectrics.

11 Jun 2013

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.

10 Jun 2013

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.

7 Jun 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

Researchers develop RNA aptamers that inhibit HCV replication

Treatments against hepatitis C virus have only been partially successful. A major problem is that antivirals generate drug resistance. Now Seong-Wook Lee of Dankook University, Yongin, Republic of Korea and his collaborators have developed agents that bind to the business end of a critical protein, disabling it so successfully that no resistance has arisen.

3 Jun 2013

Study supports future possibility of personalized medicine for cervical cancer

Doctors at Washington University School of Medicine in St. Louis have shown that testing cervical tumors before treatment for vulnerability to chemotherapy predicts whether patients will do well or poorly with standard treatment.

1 Jun 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

Raman spectroscopy algorithm has potential to diagnose breast lesions with high precision

A newly developed, single-step Raman spectroscopy algorithm has the potential to simultaneously detect microcalcifications and enable diagnosis of the associated breast lesions with high precision, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

31 May 2013

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013

Researchers develop multicolor fluorescence labeling method to identify tumor specific miRNAs

In recent years, microRNAs and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers.

27 May 2013

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.

23 May 2013

LDCT helps identify earliest stages of lung cancer

A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate the earliest stages of the disease.

22 May 2013

Measuring genetic diversity within tumor predicts outcomes of patients with head and neck cancer

A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer.

20 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

Clinical guide on endometrial assessment in peri and postmenopausal women published in Maturitas

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society in the journal Maturitas on endometrial assessment in peri and postmenopausal women with summary recommendations.

8 May 2013

Carcinoma News and Research

Further Reading